S&P Futures
4,138.00 +5.75 (+0.14%) Dow Futures
34,056.00 -92.00 (-0.27%) Nasdaq Futures
12,507.25 +93.00 (+0.75%) Russell 2000 Futures
1,964.90 -3.50 (-0.18%) Crude Oil
77.08 +0.67 (+0.88%) Gold
1,967.70 +24.90 (+1.28%)
Benitec Biopharma Inc. (BNTC)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.2300 |
| Open | 0.2300 |
| Bid | 0.2391 x 4000 |
| Ask | 0.2400 x 4000 |
| Day's Range | 0.2154 - 0.2467 |
| 52 Week Range | 0.1310 - 3.0500 |
| Volume | |
| Avg. Volume | 403,506 |
| Market Cap | 1.862M |
| Beta (5Y Monthly) | 1.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.8000 |
| Earnings Date | Feb 13, 2023 - Feb 17, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- GlobeNewswire
Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program
HAYWARD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced the enrollment of the first oculopharyngeal muscular dystrophy (OPMD) patient into the OPMD natural history phase of the BB-301 clinical development program. The OPMD Natural History (NH) S
- GlobeNewswire
Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update
HAYWARD, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Fiscal Year First Quarter ended September 30, 2022. The Company has filed its quarterly report on Form 10-Q for the quarter ended September 30, 2022, with the U.S.
- GlobeNewswire
Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering
HAYWARD, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced it closed its previously announced underwritten public offering of 29,809,471 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying
